Dissecting the structural determinants of the interaction between the human cytomegalovirus UL18 protein and the CD85j immune receptor

被引:8
|
作者
Occhino, Marzia [1 ]
Ghiotto, Fabio [1 ]
Soro, Simonetta [2 ]
Mortarino, Mimosa [4 ]
Bosi, Stefania [2 ]
Maffei, Massimo [1 ]
Bruno, Silvia [1 ]
Nardini, Marco [5 ,6 ]
Figini, Mariangela [4 ]
Tramontano, Anna [2 ,3 ]
Ciccone, Ermanno [1 ]
机构
[1] Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy
[2] Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy
[3] Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy
[4] Ist Nazl Tumori, Dept Expt Oncol, Mol Therapy Unit, I-20133 Milan, Italy
[5] Univ Milan, Dept BioMol Sci & Biotechnol, Milan, Italy
[6] Univ Milan, Consiglio Nazl Ric Ist Nazl Fis Mat, Milan, Italy
来源
JOURNAL OF IMMUNOLOGY | 2008年 / 180卷 / 02期
关键词
D O I
10.4049/jimmunol.180.2.957
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
UL18 is a glycoprotein encoded by the human cytomegalovirus genome and is thought to play a pivotal role during human cytomegalovirus infection, although its exact function is still a matter of debate. UL18 shares structural similarity with MHC class I and binds the receptor CD85j on immune cells. Besides UL18, CD85j binds MHC class I molecules. The binding properties of CD85j to MHC class I molecules have been thoroughly studied. Conversely, very little information is available on the CD85j/UL18 complex, namely that UL18 binds CD85j through its alpha 3 domain with an affinity that is similar to 1000-fold higher than the MHC class I affinity for CD85j. Deeper knowledge of features of the UL18/CD85j complex would help to disclose the function of UL18 when it binds to CD85j. In this study we first demonstrated that the UL18 alpha 3 domain is not sufficient per se for binding and that beta(2)-microglobulin is necessary for UL18-CD85j interaction. We then dissected structural determinants of binding UL18 to CD85j. To this end, we constructed a three-dimensional model of the complex. The model was used to design mutants in selected regions of the putative interaction interface, the effects of which were measured on binding. Six regions in both the alpha 2 and alpha 3 domains and specific amino acids within them were identified that are potentially involved in the UL18-CD85j interaction. The higher affinity of UL18 to CD85j, compared with MHC class 1, seems to be due not to additional interaction regions but to an overall better fit of the two molecules.
引用
收藏
页码:957 / 968
页数:12
相关论文
共 25 条
  • [21] Dynamic Shift from CD85j/ILT-2 to NKG2D NK Receptor Expression Pattern on Human Decidual NK during the First Trimester of Pregnancy
    Marlin, Romain
    Duriez, Marion
    Berkane, Nadia
    de Truchis, Claire
    Madec, Yoann
    Rey-Cuille, Marie-Anne
    Cummings, Jean-Saville
    Cannou, Claude
    Quillay, Heloise
    Barre-Sinoussi, Francoise
    Nugeyre, Marie-Therese
    Menu, Elisabeth
    PLOS ONE, 2012, 7 (01):
  • [22] Interaction between the assembly of the ribosomal subunits: Disruption of 40S ribosomal assembly causes accumulation of extra-ribosomal 60S ribosomal protein uL18/L5
    Rahman, Nusrat
    Shamsuzzaman, Md
    Lindahl, Lasse
    PLOS ONE, 2020, 15 (01):
  • [23] Expression of human inhibitory receptor Ig-like transcript 2 (ILT2/LILRB1/LIR1/CD85j) in vivo facilitates the regulatory activity of CD4+CD25-programmed death-1+T cells
    Zhang, Wei
    Liang, Siyuan
    Horuzsko, Anatolij
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S167 - S168
  • [24] ACTIVATION OF HUMAN NEUTROPHILS INDUCES AN INTERACTION BETWEEN THE INTEGRIN-BETA-2-SUBUNIT (CD18) AND THE ACTIN-BINDING PROTEIN ALPHA-ACTININ
    PAVALKO, FM
    LAROCHE, SM
    JOURNAL OF IMMUNOLOGY, 1993, 151 (07): : 3795 - 3807
  • [25] ROLE OF N-LINKED GLYCANS IN THE INTERACTION BETWEEN THE ENVELOPE GLYCOPROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS AND ITS CD4 CELLULAR RECEPTOR - STRUCTURAL ENZYMATIC ANALYSIS
    FENOUILLET, E
    CLERGETRASLAIN, B
    GLUCKMAN, JC
    GUETARD, D
    MONTAGNIER, L
    BAHRAOUI, E
    JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (03): : 807 - 822